exv10w1



 





Exhibit 10.1




EMPLOYMENT AGREEMENT




     This employment agreement (the “Agreement”) is entered into as of July 27, 2007 between
OXiGENE, Inc., a Delaware corporation (“OXiGENE”), and Patricia Walicke (the “Executive”).



WITNESSETH:




     WHEREAS, OXiGENE and Executive desire to enter into an employment agreement relating to the
position of OXiGENE’s Vice President and Chief Medical Officer.



     NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are
hereby mutually acknowledged, OXiGENE and Executive hereby agree as follows:



1. Employment




          1.1 Executive shall serve in the capacity of Vice President and Chief Medical Officer, and
shall have the duties, responsibilities and authority assigned to Executive by OXiGENE’s President
and Chief Executive Officer to whom she shall report.




     Executive, so long as she is employed hereunder, (i) shall devote substantially all of her
full professional time and attention to the services required of her as an employee of OXiGENE,
except as otherwise agreed and except as permitted in accordance with paid vacation time subject to
OXiGENE’s existing vacation policy, and subject to OXiGENE’s existing policies pertaining to
reasonable periods of absence due to sickness, personal injury or other disability, (ii) shall use
her best efforts to promote the interests of OXiGENE, and (iii) shall discharge her
responsibilities in a diligent and faithful manner, consistent with sound business practices.
Notwithstanding the above, the Executive may continue to serve as a consultant / advisor for the
entities listed on Exhibit A provided that such service does not create any conflicts, ethical or
otherwise, with Executive’s responsibilities to OXiGENE and further provided that Executive’s time
commitments do not unreasonably interfere with her fulfillment of her responsibilities hereunder,
as determined by OXiGENE.



2. Term




     The term of Executive’s employment under this Agreement shall commence at a date mutually
agreed upon by the parties and shall continue until terminated by either party in accordance with
Section 6 hereof (the “Employment Term”).



3. Base Salary; Stock Options, Sign-on Bonus




          3.1 During the Employment Term, Executive initially shall be paid an annual base salary in the
amount of $300,000 (such amount as adjusted, from time to time, the “Base Salary”), payable in
biweekly (26) installments in accordance with OXiGENE’s


 









 







payroll schedule from time to time in effect. The Base Salary will be subject to review annually or on such periodic basis (not to
exceed annually) as OXiGENE reviews the compensation of OXiGENE’s other senior executives and may
be adjusted upwards in the sole discretion of the Board of Directors of OXiGENE (the “Board”) or
its designee. Executive will be eligible during each year of the Employment Term for consideration
for annual bonus (the “Annual Bonus”) equal to 25% of her then-current Base Salary, based upon
OXiGENE’s assessment of the performance of Executive and OXiGENE at the sole discretion of OXiGENE,
to be paid prior to March 15th of the year following the year in which the Annual Bonus is earned.
The Annual Bonus is based on the achievement of individual and Company written goals established on
an annual basis and on overall Company performance. Executive shall be eligible for a pro-rated
Annual Bonus for 2007. The Board may in its discretion award Executive a more generous bonus.



OXiGENE shall grant to Executive, subject to approval by the Compensation Committee of the Board,
options to purchase 200,000 shares of OXiGENE’s common stock at an exercise price equal to the fair
market value of such stock on the date of grant pursuant to and in accordance with the terms of
OXiGENE’s 2005 Stock Plan (the “Stock Plan”) and OXiGENE’s standard form of option agreement within
60 days of Executive’s first day of employment. To the extent allowed by law, the options shall be
treated as incentive options. The options shall vest in four equal annual increments over the four
(4) year period measured from the date of grant of such options, with vesting to begin on the one
(1) year anniversary of the grant date. In addition, Executive shall be eligible to receive stock
option grants, stock bonuses, restricted stock grants or other equity compensation awards granted
to Executive from time to time by the Board in its sole discretion and to participate in any equity
compensation plan that may be established by OXiGENE for Executive or its executive team generally.



Executive shall earn a $30,000 signing bonus, payable on the first payroll following the first day
of employment. If Executive’s employment hereunder is terminated either by OXiGENE for Cause or
voluntarily by Executive in the absence of a Good Reason (as defined in Section 6.6) within one (1)
year of the Commencement Date, Executive will promptly repay a portion of the Commencement Bonus
equal to the amount of the Commencement Bonus, net of applicable taxes and deductions, multiplied
by a fraction, the numerator of which equals the number of days from the effective date of such
termination to the first anniversary of the Commencement Date and the denominator of which will be
365 (or OXiGENE may withhold such amount from any payments otherwise due to Executive).




4. Benefits




     Executive shall be entitled to participate in employee benefit plans and arrangements made
available by OXiGENE generally to OXiGENE employees of comparable rank during the Employment Term.



5. Business Expenses




 









 








          5.1 The Executive shall be entitled to receive an American Express Corporate Card (or other
card should OXiGENE change to another card issuer), for business related expenses and prompt
reimbursement will be made for all reasonable and customary expenses incurred by her in performing
services hereunder during the Employment Term; provided that such expenses are incurred and
accounted for in accordance with the policies and procedures established by OXiGENE.




          5.2 If the Executive relocate as result of business needs and at the request of the Company,
the Company shall reimburse Employee for up to $75,000 for Relocation Expenses (as defined below)
relating to such relocation so long as the Employee is employed by the Company at the time of the
relocation. Such reimbursement shall be made provided that such expenses are incurred and
accounted for in accordance with the policies and procedures established by OXiGENE. “Relocation
Expenses” shall mean reasonable expenses incurred by the Employee related to costs of the physical
movement of all goods and vehicles that are in Employee’s California home, up to three round trip
airfares and hotel accommodations for “house hunting” and up to three months of temporary housing.




6. Termination




          6.1 The Executive may resign from employment with OXiGENE upon written notice to OXiGENE.




          6.2 If the Executive’s employment is terminated by OXiGENE other than for Cause (as defined
below) or the Executive’s disability, then OXiGENE shall provide to Executive the following
termination compensation:





	 	(a)	 	payments equal to Executive’s then-current Base Salary for a
period of twelve (12) months, payable on OXiGENE’s normal paydays.
	 
	 	(b)	 	a payment equal to the portion of the Executive’s Base Salary
that has accrued prior to any termination of the Executive’s employment with
OXiGENE that has not yet been paid;
	 
	 	(c)	 	to the extent required by law and OXiGENE’s policy, an amount
equal to the value of the Executive’s accrued but unused vacation days;
	 
	 	(d)	 	the amount of any expenses properly incurred by the Executive
on behalf of OXiGENE prior to any termination and not yet reimbursed;
	 
	 	(e)	 	the Annual Bonus related to the most recently completed
calendar year, if not already paid, and




 









 












	 	(f)	 	should Executive timely elect and be eligible for COBRA
coverage, payment of Executive’s COBRA premiums for the Executive and the
Executive’s immediate family’s medical and dental insurance coverage for a
period of twelve (12) months; provided, that OXiGENE shall have no obligation
to provide such coverage if Executive becomes eligible for medical and dental
coverage with another employer. Executive shall give prompt written notice to
the Company on attaining such eligibility.





     Notwithstanding anything to the contrary herein, OXiGENE’s obligation to provide the
termination compensation described in this Section 6.2 (except for pursuant to (b), (c), (d) and
(e)) shall be conditional upon the Executive delivering to OXiGENE, and not thereafter revoking, a
fully executed general release, in a form satisfactory to OXiGENE, of all claims against OXiGENE,
its affiliates, and each of their officers, directors, employees, agents and attorneys. Such
payments described in Sections 6.2(a),, (e) and (f), unless otherwise required by law, shall become
due on the first payday which is at least ten (10) business days after the Executive delivers to
OXiGENE said release.



          6.3 If, following any Change in Control (as such term is defined below) and prior to the
expiration of one (1) year from the date of such Change in Control, (1) Executive’s employment is
terminated (other than for Cause or the Executive’s disability) or (2) in the event of a
termination with Good Reason, then





	 	(a)	 	The Executive shall receive, as soon as practicable after the
termination date:






(i) An amount equal to twelve (12) months of Executive’s then current Base
Salary; and





(ii) the termination compensation described in Sections 6.2(b), (c), (d),
(e) and (f) above.




	 	(b)	 	All stock options, stock appreciation rights, restricted
stock, and other incentive compensation granted to the Executive by OXiGENE
shall vest and be immediately exercisable. Executive may exercise all such
vested options and rights, and shall receive payments and distributions
accordingly




“Change in Control” shall mean the occurrence of any of the following events:





(i) Ownership. Any “Person” (as such term is used in Sections 13(d) and 14(d) of
the Securities Exchange Act of 1934, as amended) becomes the “Beneficial Owner” (as
defined in Rule 13d-3 under said Act), directly or indirectly, of securities of
OXiGENE representing 50% or more of the total voting power represented by OXiGENE’s
then outstanding voting securities (excluding for this purpose any such voting
securities held by OXiGENE or its affiliates or by any employee benefit plan of
OXiGENE)



 









 







pursuant to a transaction or a series of related transaction which the
Board of Directors does not approve; or




(ii) Merger/Sale of Assets. (A) A merger or consolidation of OXiGENE whether or
not approved by the Board of Directors, other than a merger or consolidation which
would result in the voting securities of OXiGENE outstanding immediately prior
thereto continuing to represent (either by remaining outstanding or by being
converted into voting securities of the surviving entity or the parent of such
corporation) at least 50% of the total voting power represented by the voting
securities of OXiGENE or such surviving entity or parent of such corporation, as
the case may be, outstanding immediately after such merger or consolidation; or (B)
the stockholders of OXiGENE approve an agreement for the sale or disposition by
OXiGENE of all or substantially all of OXiGENE’s assets; or




(iii) Change in Board Composition. A change in the composition of the Board of
Directors, as a result of which fewer than a majority of the directors are
Incumbent Directors. “Incumbent Directors” shall mean directors who either (A) are
directors of OXiGENE as of the date of this Agreement, or (B) are elected, or
nominated for election, to the Board of Directors with the affirmative votes of at
least a majority of the Incumbent Directors at the time of such election or
nomination (but shall not include an individual whose election or nomination is in
connection with an actual or threatened proxy contest relating to the election of
directors to OXiGENE).



          6.4 Except as otherwise set forth in this Section 6 or as required by applicable law, all
obligations of OXiGENE under this Agreement shall cease if, during the Employment Term, OXiGENE
terminates Executive for Cause or the Executive resigns her employment for other than Good Reason.
Upon such termination, Executive shall be entitled to receive only the termination compensation
described under Sections 6.2(b), (c), (d) and (e).




          6.5 For the purposes of this Agreement, the term “Cause” shall mean any of the following:





	 	(a)	 	the Executive’s substantial failure to perform any of her duties
hereunder or to follow reasonable, lawful directions of the Board or any officer to
whom the Executive reports;
	 
	 	(b)	 	the Executive’s willful misconduct or willful malfeasance in connection
with her employment;
	 
	 	(c)	 	the Executive’s conviction of, or plea of nolo contendere to, any crime
constituting a felony under the laws of the United States or any state thereof, or
any other crime involving moral turpitude;
	 
	 	(d)	 	the Executive’s material breach of any of the provisions of this
Agreement, OXiGENE’s bylaws or any other agreement with OXiGENE; or




 









 












	 	(e)	 	the Executive’s engaging in misconduct which has caused significant
injury to OXiGENE, financial or otherwise, or to OXiGENE’s reputation; or
	 
	 	(f)	 	any act, omission or circumstance constituting cause under the law governing this
Agreement.





     If Cause arises under Section 6.5(a), (b), (d), (e), or (f) the Executive shall be given a
minimum period of thirty (30) days to reasonably cure such Cause (if reasonably subject to cure).



          6.6 For the purposes of this Agreement, “Good Reason” shall mean: (i) without the Executive’s
express written consent, any material reduction in Executive’s title, or responsibilities compared
to those prior to a Change in Control (as such term is defined in Section 6.3); (ii) relocation of
more than 60 miles; (iii) without the Executive’s express written consent, a material reduction by
OXiGENE in the Executive’s total compensation as in effect on the date hereof or as the same may be
increased from time to time, provided that it shall not be deemed a material reduction if (a) the
amount of Executive’s Annual Bonus is less than the amount of any previously awarded Annual Bonuses
or (b) a benefit is amended and such amendment affects all eligible executive participants; or (iv)
the Company OXiGENE breaches a material term of this Agreement and such breach has remained uncured
for a minimum of thirty (30) days after Executive has notified OXiGENE of breach. To be effective,
such notice must be in writing and set forth the specific alleged Good Reason for termination and
the factual basis supporting the alleged Good Reason.




          6.7 The foregoing payments upon Executive’s termination shall constitute the
exclusive payments due Executive upon termination of her employment with OXiGENE
under this Agreement or otherwise, provided, however that except as stated above,
such payments shall have no effect on any benefits which may be payable to Executive
under any plan of OXiGENE which provides benefits after termination of employment.




7 Taxes.




     Any amounts or benefits payable or provided to the Executive hereunder shall be paid or
provided to the Executive subject to all applicable taxes required to be withheld by OXiGENE
pursuant to national and/or local law. The Executive shall be solely responsible for all taxes
imposed on the Executive by reason of her receipt of any amounts of compensation or benefits
payable hereunder and OXiGENE makes no representation, warranty or promise regarding the tax
treatment of any payment or benefit provided to the Executive.



8 Non-Competition / Non-Solicitation




          8.1`While the Executive is employed by OXiGENE and for a period of 12 months following
the termination of her employment (the “Noncompetition Period”), the Executive shall not,
for herself or on behalf of any other person or


 









 







entity, directly or indirectly, whether as principal, partner, agent, independent contractor, stockholder, employee, consultant,
representative or in any other capacity, own, manage, operate or control, be concerned or
connected with, or employed by, engage in or have a financial interest in any Restricted
Business (as defined in Section 8.3) anywhere in the world (the “Restricted Territory”)
except that nothing in this Agreement shall preclude the Executive from purchasing or
owning securities of any such business if such securities are publicly traded, and
provided that the Executive’s holdings do not exceed two (2%) percent of the issued and
outstanding securities of any class of securities of such business.




          8.2 In addition, during the Noncompetition Period the Executive shall not,
either individually or on behalf of or through any third party, solicit, divert or
appropriate or attempt to solicit, divert or appropriate, for the purpose of
competing with OXiGENE or any present or future parent, subsidiary or other
affiliate of OXiGENE which is engaged in the Restricted Business, any customers,
clients or vendors of OXiGENE with whom the Executive has had significant contact or
to whom the Executive has provided services during the Executive’s last two years of
employment with OXiGENE. 




          8.3 For the purposes of this Agreement, the term “Restricted Business” shall mean any person,
partnership, corporation, business organization or other entity (or a division or business unit of
any entity) whose primary business is the research, development, manufacture, marketing or selling
of products or services that are the same as or similar to those that OXiGENE is researching,
developing, manufacturing, marketing or selling during the Executive’s employment with OXiGENE,
provided that (i) after the Executive’s employment with OXiGENE has terminated, this definition
shall apply only with respect to products and services that are the same as or similar to those
that OXiGENE was engaged in or developing during the last two (2) years of her employment with
OXiGENE; (ii) nothing in this definition shall operate to prevent Executive from working for or
with respect to any subsidiary, division or affiliate (each, a “Unit”) of an entity if that Unit is
not itself a Restricted Business, irrespective of whether some other Unit of such entity
constitutes a Restricted Business (as long as the Executive does not provide any services for such
other Unit); and (iii) Restricted Business will not include researching, developing, manufacturing,
marketing or selling products or services other than those specific products (vascular disrupting
agents) being researched, developed, manufactured, marketed, or sold by or on behalf of OXiGENE
when the Executive’s employment with OXiGENE terminates.




          8.4 During the Non-Competition Period, neither the Executive nor any Executive-Controlled
Person (as defined below) will, without the prior written consent of the Board, directly or indirectly solicit for employment, or make an unsolicited
recommendation to any other person that it employ or solicit for employment any person who is or
was, at any time during the 9 month period  prior to the terminations date, an officer,
Executive or key employee of OXiGENE or any affiliate of OXiGENE. As used in this Agreement, the
term “Executive-Controlled Person” shall mean any company, partnership, firm or other entity as to
which Executive possesses, directly or indirectly,


 









 







the power to direct or cause the direction of the management and policies of such entity, whether through the ownership of voting securities, by
contract or otherwise.




          8.5 The provisions contained in this Section 8 as to the time periods, scope of activities,
persons or entities affected, and territories restricted shall be deemed divisible so that, if any
provision contained in this Section 8 is determined to be invalid or unenforceable, such provisions
shall be deemed modified so as to be valid and enforceable to the full extent lawfully permitted.




          8.6 Executive agrees that the provisions of this Section 8 are reasonable and necessary for
the protection of OXiGENE and that they may not be adequately enforced by an action for damages and
that, in the event of a material breach thereof by Executive or any Executive-Controlled Person,
OXiGENE shall be entitled to apply for and obtain injunctive relief in any court of competent
jurisdiction to restrain the breach or threatened breach of such violation or otherwise to enforce
specifically such provisions against such violation, without the necessity of the posting of any
bond by OXiGENE. Executive further covenants under this Section 8, that OXiGENE shall be entitled
to an accounting and repayment of all profits, compensation, commissions, remuneration or other
benefits that Executive directly or indirectly has realized and/or may realize as a result of,
growing out of or in connection with any such violation. Such a remedy shall, however, be
cumulative and not exclusive and shall be in addition to any injunctive relief or other legal
equitable remedy to which OXiGENE is or may be entitled




9 Indemnification




     OXiGENE, to the extent permitted by its Articles and By Laws, shall indemnify the Executive
for all claims, losses, expenses, costs, obligations, and liabilities of every nature whatsoever
incurred by the Executive to any third party as a result of the Executive’s acts or omissions as an
employee of OXiGENE, but excluding from such indemnification any claims, losses, expenses, costs,
obligations, or liabilities incurred by the Executive as a result of the Executive’s bad faith,
willful misconduct or gross negligence.



10 Attorney’s Fees and Expenses




     OXiGENE and the Executive agree that in the event of litigation arising out of or relating to
this Agreement, the prevailing party shall be entitled to reimbursement from the other party to the
prevailing party’s reasonable attorney fees and expenses.



11 Amendments




     This Agreement may not be altered, modified or amended except by a written instrument signed
by each of the parties hereto.



12 Assignments




 









 








     Neither this Agreement nor any of the rights or obligations hereunder shall be assigned or
delegated by any party hereto without the prior written consent of the other party;
provided, however, that any payments and benefits owed to Executive under this
Agreement shall inure to the benefit of her heirs and personal representatives.



13 Waiver




     Waiver by any party hereto of any breach or default by any other party of any of the terms of
this Agreement shall not operate as a waiver of any other breach or default, whether similar to or
different from the breach or default waived.



14 Severability




     In the event that any one or more of the provisions of this Agreement shall be or become
invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the
remaining provisions contained herein shall not be affected thereby.



15 Notices




     All notices and other communications provided for in this Agreement shall be in writing and
shall be deemed to have been duly given when personally delivered or when mailed by registered
mail, return receipt requested, postage prepaid, addressed as follows:



     If to Executive, to her as follows:



     If to OXiGENE, to it as follows:


OXiGENE, Inc.

230 Third Avenue

Waltham, MA 02451

Attn: Richard Chin or his successor



Or to such other address or such other person as Executive or OXiGENE shall designate in writing in
accordance with this Section 15, except that notices regarding changes in notices shall be
effective only upon receipt.




16 Headings




     Headings to Sections in this Agreement are for the convenience of the parties only and are not
intended to be a part of, or to affect the meaning or interpretation of, this Agreement.



17 Governing Law; Venue; Jury Waiver




 









 








     This Agreement shall be governed by the laws of the Commonwealth of Massachusetts without
reference to the principles of conflict of laws. Each of the parties hereto consents to the
jurisdiction of the federal and state courts of the Commonwealth of Massachusetts in connection
with any claim or controversy arising out of or connected with this Agreement, and said courts
shall be the exclusive fora for the resolution of any such claim or controversy. Service of
process in any such proceeding may be made upon each of the parties hereto at the address of such
party as determined in accordance with Section 15 of this Agreement, subject to the applicable
rules of the court in which such action is brought. Both the Executive and OXiGENE waive any right
they may have to a trial by jury and agree that any dispute between them arising from or relating
to the Agreement or the Executive’s employment shall be tried by a judge sitting without a jury.



18 All Other Agreements Superseded.




     Except for Executive’s Confidentiality and Inventions Agreement, which the Executive shall
sign as a condition of her employment and of the effectiveness of this Agreement, this Agreement
contains the entire agreement between Executive and OXiGENE with respect to all matters relating to
Executive’s employment with OXiGENE and, as of the date hereof, will supersede and replace any
other agreements, written or oral, between the parties relating to the terms or conditions of
Executive’s employment with OXiGENE.



     IN WITNESS WHEREOF, OXiGENE and Executive have caused this Agreement to be executed as of the
date first above written.



	 	 	 	 	 
	 	 	 
	 	                                                  /s/ Patricia Walicke
 	 
	 	Patricia Walicke
 	 
	 	July 31, 2007
Start Date 	 
	 
	 	OXiGENE, Inc.

 	 
	 	By:  	/s/ Richard Chin
 	 
	 	 	Name:  	Richard Chin 	 
	 	 	Title:  	President & CEO 	 



 









 






	 	 	 	 	 



Exhibit A




VLST (Viral Logic Systems Technology), consultant

Barofold, consultant and Clinical Advisory Board member

SARCode, consultant and Clinical Advisory Board member

TPG Ventures, consultant

Essex Woodlands Health Ventures, consultant

Peptimmune, consultant

Kalobios, consultant




Spinal Muscular Atrophy Foundation, consultant

Retts Syndrome Foundation, consultant